Clinical Trials
218 trialsA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Memorial Sloan Kettering Cancer Center
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Sun Yat-sen University
TRIBE-C
Sun Yat-sen University
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
CLEAR-02
Fudan University
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
The First Hospital of Jilin University
Toco-CoR
Vejle Hospital
FRUITFUL
SCRI Development Innovations, LLC
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
ICARuS
Memorial Sloan Kettering Cancer Center
BBOpCo
Duke University
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
City of Hope Medical Center
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
Memorial Sloan Kettering Cancer Center
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma
Allama Iqbal Medical College
CEIL
Sun Yat-sen University
AIO-KRK-0418
Charite University, Berlin, Germany
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
University Health Network, Toronto
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
FOXHIPECT4
Maimónides Biomedical Research Institute of Córdoba
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
COCHISE
Institut Bergonié
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
University of Alabama at Birmingham
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
Sun Yat-sen University
OPTICAL-2
Sun Yat-sen University
COLAGE
GERCOR - Multidisciplinary Oncology Cooperative Group
OSCAR
Federation Francophone de Cancerologie Digestive
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
City of Hope Medical Center
FIRE-11
Charite University, Berlin, Germany
CONVERSION
University of Saskatchewan
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
NIVACOR
Gruppo Oncologico Italiano di Ricerca Clinica
PANIRINOX
UNICANCER
CAIRO5
Dutch Colorectal Cancer Group
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
CLavSyn
Centre Hospitalier Universitaire de Besancon
AVETRIC
Gruppo Oncologico del Nord-Ovest